Rafael Holdings (RFL) Completes Merger with Cyclo Therapeutics (CYTH) Following Shareholder Approvals Mar 26, 2025 06:50AM
Cyclo Therapeutics (CYTH) Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC Sub-Study Feb 7, 2025 08:05AM
Pacira BioSciences (PCRX) Appoints Shawn Cross as Chief Financial Officer Oct 21, 2024 08:00AM
Cyclo Therapeutics (CYTH) Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 Sep 5, 2024 09:05AM
Maxim Group Downgrades Cyclo Therapeutics (CYTH) to Hold Aug 27, 2024 08:44AM


Aug 26, 2024 05:03AM Cyclo Therapeutics (CYTH) PT Lowered to $0.95 at Ascendiant Capital
Aug 23, 2024 06:34AM H.C. Wainwright Downgrades Cyclo Therapeutics (CYTH) to Neutral
Aug 22, 2024 06:50AM Rafael Holdings (RFL) and Cyclo Therapeutics (CYTH) Enter into Definitive Merger Agreement
Jul 29, 2024 09:09AM Cyclo Therapeutics (CYTH) Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office